摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(6-bromo-quinoxalin-2-yl)[(R)-1-(3-methoxy-phenyl)ethyl]amine | 1257090-13-3

中文名称
——
中文别名
——
英文名称
(6-bromo-quinoxalin-2-yl)[(R)-1-(3-methoxy-phenyl)ethyl]amine
英文别名
(6-Bromo-quinoxalin-2-yl)-[(r)-1-(3-methoxy-phenyl)-ethyl]-amine;6-bromo-N-[(1R)-1-(3-methoxyphenyl)ethyl]quinoxalin-2-amine
(6-bromo-quinoxalin-2-yl)[(R)-1-(3-methoxy-phenyl)ethyl]amine化学式
CAS
1257090-13-3
化学式
C17H16BrN3O
mdl
——
分子量
358.238
InChiKey
HFOOGVANYGEZFG-LLVKDONJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    47
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-Boc-吡唑-4-硼酸频哪醇酯(6-bromo-quinoxalin-2-yl)[(R)-1-(3-methoxy-phenyl)ethyl]aminebis(tri-tert-butylphosphine)palladium(0) 、 potassium iodide caesium carbonate盐酸 作用下, 以 1,4-二氧六环 为溶剂, 反应 4.0h, 生成 [1(R)-1-(3-methoxy-phenyl)ethyl][6-(1H-pyrazol-4-yl)quinoxalin-2-yl]amine hydrochloride
    参考文献:
    名称:
    [EN] SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE
    [FR] BENZOTRIAZINES ET QUINOXINALINES SUBSTITUÉES COMME INHIBITEURS DE LA P7OS6 KINASE
    摘要:
    该发明提供了式(1)的化合物或其盐或互变异构体;其中X1为N或N+(O-);X2为N或CH;Q为C1-3烷基基团;R1从氢、C1-4烃基和羟基-C2-4烃基中选择;R2、R3和R4相同或不同,每个从氢、氟、氯和甲基中选择;Ar1为含有0、1或2个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员芳基或杂芳基环,或者是一个萘环;Ar2为含有1、2或3个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员杂芳基环。式(1)的化合物是p70S6激酶的抑制剂,可用于治疗增殖性疾病。
    公开号:
    WO2010136755A1
  • 作为产物:
    描述:
    6-溴-2-氯喹喔啉(R)-(+)-1-(3-甲氧基苯基)乙胺二甲基亚砜 为溶剂, 反应 16.0h, 以82%的产率得到(6-bromo-quinoxalin-2-yl)[(R)-1-(3-methoxy-phenyl)ethyl]amine
    参考文献:
    名称:
    [EN] SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE
    [FR] BENZOTRIAZINES ET QUINOXINALINES SUBSTITUÉES COMME INHIBITEURS DE LA P7OS6 KINASE
    摘要:
    该发明提供了式(1)的化合物或其盐或互变异构体;其中X1为N或N+(O-);X2为N或CH;Q为C1-3烷基基团;R1从氢、C1-4烃基和羟基-C2-4烃基中选择;R2、R3和R4相同或不同,每个从氢、氟、氯和甲基中选择;Ar1为含有0、1或2个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员芳基或杂芳基环,或者是一个萘环;Ar2为含有1、2或3个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员杂芳基环。式(1)的化合物是p70S6激酶的抑制剂,可用于治疗增殖性疾病。
    公开号:
    WO2010136755A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED QUINOXALINES AND BENZOTRIAZINE P70S6 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYPE QUINOXALINES ET BENZOTRIAZINE SUBSTITUÉES DE LA P70S6 KINASE
    申请人:SENTINEL ONCOLOGY LTD
    公开号:WO2016170163A1
    公开(公告)日:2016-10-27
    The invention provides compounds that inhibit or modulate the activity of p70S6 kinase, the compounds being of the formula (0), or a salt, tautomer or N-oxide thereof; wherein: X1 is N or N+(0-); X2 is N or CH; Q1 is an optionally substituted C1-8 alkylene; Q2 is a bond or an optionally substituted C1-8 alkylene group; R1 is selected from hydrogen and a group Cy1; Cy1 is an optionally substituted 4 to 7 membered monocyclic non-aromatic carbocyclic or heterocyclic group containing 0, 1 or 2 heteroatom ring members selected from O and S and oxidised forms of S; R2, R3 and R4 are the same or different and each is selected from hydrogen, fluorine, chlorine, C1-2 alkyl and C1-2 alkoxy, wherein each C1-2 alkyl and C1-2 alkoxy is optionally substituted with two or more fluorine atoms; Ar1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring Ar2 is an optionally substituted bicyclic 8 to 1 1 -membered heteroaryl group containing 1, 2, 3 or 4 heteroatom ring members selected from O, N and S. The compounds are useful in medicine, for example in the treatment of a disease or condition selected from cancers (e.g. triple negative breast cancer, brain tumours and brain metastases arising from non-brain cancers), neurodevelopmental diseases (e.g. Fragile X syndrome) and neurodegenerative diseases.
    该发明提供了抑制或调节p70S6激酶活性的化合物,该化合物的结构如下式(0),或其盐、互变异构体或N-氧化物;其中:X1为N或N+(0-);X2为N或CH;Q1为可选择取代的C1-8烷基;Q2为键或可选择取代的C1-8烷基基团;R1选自氢和Cy1基团;Cy1为可选择取代的含有0、1或2个来自O和S的杂原子环成员的4到7成员单环非芳香碳环或杂环基团及S的氧化形式;R2、R3和R4相同或不同,每个选自氢、氟、氯、C1-2烷基和C1-2烷氧基,其中每个C1-2烷基和C1-2烷氧基可选择地取代为两个或更多氟原子;Ar1为可选择取代的含有0、1或2个来自O、N和S的杂原子环成员的单环5或6成员芳基或杂芳基环,或一个萘环;Ar2为可选择取代的含有1、2、3或4个来自O、N和S的杂原子环成员的双环8到11成员杂芳基基团。这些化合物在医学上有用,例如在治疗癌症(如三阴性乳腺癌、脑肿瘤和来自非脑部癌症的脑转移瘤)、神经发育疾病(如脆性X综合征)和神经退行性疾病等疾病或病况的治疗中。
  • SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE
    申请人:Boyle Robert George
    公开号:US20120071478A1
    公开(公告)日:2012-03-22
    The invention provides compounds of the formula (1): or salts or tautomers thereof; wherein X 1 is N or N + (O − ); X 2 is N or CH; Q is a C 1-3 alkylene group; R 1 is selected from hydrogen, C 1-4 hydrocarbyl and hydroxy-C 2-4 hydrocarbyl; R 2 , R 3 and R 4 are the same or different and each is selected from hydrogen, fluorine, chlorine and methyl; Ar 1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring and Ar 2 is an optionally substituted monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S. The compounds of formula (1) are inhibitors of p70S6 kinase and are useful in the treatment of proliferative diseases.
    本发明提供公式(1)的化合物:或其盐或互变异构体;其中X1为N或N +(O-); X2为N或CH; Q为C1-3烷基基团; R1选择自氢,C1-4烃基和羟基-C2-4烃基; R2,R3和R4相同或不同,且每个选择自氢,氟,氯和甲基; Ar1为含有0、1或2个杂环环成员(选自O,N和S)的可选择取代的单环5或6成员芳基或杂芳基环,或萘环;Ar2为含有1、2或3个杂环环成员(选自O,N和S)的可选择取代的单环5或6成员杂芳基环。公式(1)的化合物是p70S6激酶的抑制剂,可用于治疗增生性疾病。
  • Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase
    申请人:Boyle Robert George
    公开号:US08716473B2
    公开(公告)日:2014-05-06
    The invention provides compounds of the formula (1): or salts or tautomers thereof; wherein X1 is N or N+(O−); X2 is N or CH; Q is a C1-3 alkylene group; R1 is selected from hydrogen, C1-4 hydrocarbyl and hydroxy-C2-4 hydrocarbyl; R2, R3 and R4 are the same or different and each is selected from hydrogen, fluorine, chlorine and methyl; Ar1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring and Ar2 is an optionally substituted monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S. The compounds of formula (1) are inhibitors of p70S6 kinase and are useful in the treatment of proliferative diseases.
    本发明提供式(1)的化合物或其盐或互变异构体; 其中X1为N或N+(O−); X2为N或CH; Q为C1-3烷基; R1选自氢,C1-4烃基和羟基-C2-4烃基; R2,R3和R4相同或不同,且每个选自氢,氟,氯和甲基; Ar1为可选取代的单环5或6成员芳基或杂芳基环,其中包含0,1或2个杂原子环成员,选自O,N和S,或萘环;Ar2为可选取代的单环5或6成员杂芳基环,其中包含1,2或3个杂原子环成员,选自O,N和S。式(1)的化合物是p70S6激酶的抑制剂,可用于治疗增殖性疾病。
  • SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE
    申请人:Sentinel Oncology Limited
    公开号:EP2435423B1
    公开(公告)日:2014-10-15
  • US8716473B2
    申请人:——
    公开号:US8716473B2
    公开(公告)日:2014-05-06
查看更多